@article {2199, title = {The Impact of Kaempferia galanga L. Extract on Nerve Growth Factor Expression in A Rat Model of Traumatic Brain Injury}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {December 2023}, pages = {1236-1243}, type = {Research Article}, chapter = {1236}, abstract = {

Introduction: Head injuries contribute significantly to morbidity and mortality globally, and there is need of effective treatment. This study focuses on evaluating NGF (Nerve Growth Factor) expression in a rat model of traumatic brain injury, exploring the potential therapeutic effects of Kaempferia galanga L. extract. Methods: Male Wistar rats were used in the experiment, and traumatic brain injury was induced using Marmarou{\textquoteright}s weight drop model. Four groups of rats were studied: a negative control group, a group with traumatic brain injury without Kaempferia galanga L. extract, and two groups with traumatic brain injury treated with different doses of Kaempferia galanga L. extract. Rats were divided further based on the time of decapitation, either 24 or 48 hours post-injury. NGF expression was assessed using immunohistochemistry. Results: The study confirmed NGF expression variations among groups, with stronger expression observed 48 hours post-injury in rats receiving 1200 mg/kgbb of Kaempferia galanga L. extract. This suggests a potential impact of the extract on NGF expression, likely attributed to its anti-inflammatory and antioxidant properties. Discussion: Kaempferia galanga L. extract has known anti-inflammatory and antioxidant effects, which may contribute to increased NGF expression observed in this study. Conclusion: This study sheds light on the potential benefits of Kaempferia galanga L. extract in promoting NGF expression and improving outcomes in traumatic brain injury, emphasizing the need for further investigation to translate these findings into clinical practice.

}, keywords = {kaempferia galanga, Nerve Growth Factor, Traumatic Brain Injury}, doi = {10.5530/pj.2023.15.224}, author = {Muhammad Fauzan Jauhari and Lucia Yovita Hendrati and Agus Turchan and Asra Al Fauzi and Budi Utomo and Eko Agus Subagio} } @article {1926, title = {Kaempferia galanga L. Extract Administration Attenuate Aquaporin-4 Expression in Traumatic Brain Injury: An Experimental Study in Rats}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {893-897}, type = {Original Article }, chapter = {893}, abstract = {

Introduction: Traumatic brain injury (TBI) is still a major health problem in the world. It might cause long-term disability that affect socio-economic life and become nation health burden. Post-traumatic cerebral edema might develop and commit to an unfavorable prognosis. Aquaporin 4 (AQP4) is water channel protein and a key regulator of water metabolism in the brain. Although the mechanism of AQP4 in the regulation of post-traumatic brain edema remains controversial, AQP4-lacking mice show better survival and decreased brain edema. Thus, novel strategies that suppress AQP4 become a potential field. We hypothesized that Kaempferia galanga L. may suppress brain expression of AQP4 following TBI and possibly limit the development of cerebral edema due to its neuroinflammation properties. Method: We conducted TBI to experimental rats, then given Kaempferia galanga L. extract at a dose of 600 mg/kg BW and 1200 mg/kg BW. Evaluation intensity of AQP4 expression by immunohistochemistry was performed 24 and 48 hours later to see its therapeutic effect. Results: Administration of Kaempferia galanga L. extract at a dose of 1200 mg/kg BW showed weak expression of AQP4 in all samples, both 24 and 48 hours following traumatic brain injury treatment. Conclusions: Intensity of AQP4 expression in rats{\textquoteright} brain was lower at 24 and 48 hours after TBI in rats receiving Kaempferia galanga L. extract with dose 1200 mg/ kg BW compared to the other groups. Our result indicates that Kaempferia galanga L. might affect the expression of brain AQP4 in a dose-dependent manner.

}, keywords = {Ayuverdic medicine, Neuroinflammation, Neurotrauma, Post-traumatic cerebral edema}, doi = {10.5530/pj.2022.14.185}, author = {Fajar Herbowo Niantiarno and Agus Turchan and Myrna Adianti and Budi Utomo and Muhammad Arifin Parenrengi and Abdul Hafid Bajamal} } @article {1779, title = {Mechanism of the Bioactive Sargassum cristaefolium in Inhibiting Inflammatory Mediators in a Nitroglycerin-Induced Migraine Model in Rats}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {April 2022}, pages = {388-396}, type = {Research Article }, chapter = {388}, abstract = {

Background: Migraine headaches are a form of sterile neurogenic inflammation. The sterile inflammatory process of the trigeminal nerve releases the vasoactive neuropeptide CGRP which stimulates the release of inflammatory mediators. In the incidence of migraine there is an increase in TNF-α and IL-10. Sargassum cristaefolium ethanol extract contains flavonoids, alkaloids, triterpenoids, steroids, and tannins, which has analgesic and anti-inflammatory function. Method: Sargassum cristaefolium was extracted using maceration method with 70\% ethanol as solvent. Animal models were divided into 5 groups and given NTG induction 5 times with 1 day intervals, treated for 3 weeks. All data were analyzed using IBM SPSS version 26.0. Results: Sargassum cristaefolium ethanol extract - CGRP levels β: -0.26, p: 0.17; Sargassum cristaefolium ethanol extract - CGRP expression β: -0.04, p: 0.85; Sargassum cristaefolium ethanol extract - TNF-α levels β: -0.63, p: 0.01; Sargassum cristaefolium ethanol extract - TNF-α expression β: -0.40, p: 0.04; Sargassum cristaefolium ethanol extract - IL-10 levels β: 0.77, p: 0.00; Sargassum cristaefolium ethanol extract - IL-10 expression β: 0.45, p: 0.01. Conclusions: A significant path between the administration of Sargassum cristaefolium ethanol extract and a decrease in TNF-α and an increase in IL-10. But the effect of giving Sargassum cristaefolium ethanol extract on CGRP levels did not have a significant relationship.

}, keywords = {Inflammatory mediator, Migraine, Nitroglycerin, Sargassum cristaefolium}, doi = {10.5530/pj.2022.14.50}, author = {Olivia Mahardani Adam and Jusak Nugraha and Muhammad Hamdan and Agus Turchan} } @article {1712, title = {In silico Study on the Promising Active Components of Terpenoid and Fucoidon from Sargassum sp. in Inhibiting CGRP and TNF-α}, journal = {Pharmacognosy Journal}, volume = {13}, year = {2021}, month = {December 2021}, pages = {1715-1719}, type = {Research Article}, chapter = {1715}, abstract = {

Introduction: The new discovery of the active substance in Sargassum sp marks the new era for drug industry as it is very effective as the new migraine medication compared to analgesics which have already been popular previously in treating migraine. By using the in silico methods, this study intended to identify the preventive effect of the active substance in Sargassum sp within the stage of pain and inflammation development in migraine. In migraine pathophysiology, the clinical findings would build and verify the role of CGRP and TNF-α. Methods: This research applied a one-shot experimental study and by employing the potential test through PubChem (https://pubchem.ncbi.nlm.nih.gov/), the result of this study proved that tannins, terpenoids and fucoidone were contained in the active substance of Sargassum sp leading to the possession of potential as the drug to treat migraine. Results: Terpenoids and tannin binding affinity value is higher than other substances. Terpenoids and fucoidon had similar amino acid residues with controls. Seaweed metabolites have great potential as inhibitors of CGRP and TNF-α because the binding affinity score is close to control. Conclusion: The active substance in Sargassum sp has an inhibitory effect on the occurrence of CGRP and TNF-α in migraine based on in silico studies.

}, keywords = {CGRP, Fucoidone, in silico, Sargassum sp., Terpenoid, TNF-α.}, doi = {10.5530/pj.2021.13.221}, author = {Olivia Mahardani Adam and Jusak Nugraha and Mohammad Hasan Machfoed and Agus Turchan} }